PUBLISHER: IMARC | PRODUCT CODE: 1561565
PUBLISHER: IMARC | PRODUCT CODE: 1561565
The global canine atopic dermatitis market size reached US$ 2.1 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 7.0 Billion by 2032, exhibiting a growth rate (CAGR) of 13.8% during 2024-2032.
Canine atopic dermatitis (CAD) is an allergic skin disease in dogs caused by allergens, such as pollens, house dust, insect bites, grass and food ingredients. It is an inherited predisposition that generally affects dogs aged between six months to three years. It commonly affects the ventral abdomen, mouth, eyes, interdigital skin, ear pinnae, carpal, elbow and perineal area of the animals. CAD is characterized by various symptoms, such as excessive scratching, inflammation and itching around paws, underarms and face. It can be treated by immuno-suppressants, monoclonal anatomy and glucocorticoids. They can be administered through oral, injectables and topical medications. It is known to be highly prevalent in German shepherds, Labradors, golden retrievers and pugs.
The increasing occurrence of CAD in domesticated dogs across the globe is one of the key factors creating a positive outlook for the market. This can be attributed to the changing environmental conditions, rising air pollution levels and prolonged exposure to allergens. Moreover, the increasing concerns and rising awareness among pet owners regarding early symptoms and signs of CAD, such as redness, greasy skin and yeasty smell, are providing a thrust to the market growth. Additionally, the widespread adoption of monoclonal antibodies for the treatment of the disease is favoring the market growth. These antibodies aid in directing the required immune response and calming the spread of the disease. In line with this, the increasing number of veterinary practitioners, hospitals and clinics dedicated to providing improved care for animals is positively impacting the market growth. Other factors, including the implementation of various government initiatives to restrict the usage of off-label human drugs on animals, along with extensive research and development (R&D) in the field of veterinary sciences, are anticipated to drive the market toward growth.
IMARC Group provides an analysis of the key trends in each sub-segment of the global canine atopic dermatitis market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on drug class type, route of administration and distribution channel.
The competitive landscape of the industry has also been examined along with the profiles of the key players being AB Science, Bimeda Inc., Bioceltix SA, Boehringer Ingelheim International GmbH, Ceva Sante Animale, Dechra Pharmaceuticals PLC, Elanco Animal Health Incorporated, Phibro Animal Health Corporation, Toray Industries Inc., Vetoquinol S.A., Virbac and Zoetis Inc.